Cencora, Inc.

Cencora, Inc.

324.10
EUR
-0.75
(-0.23%)
11.87EPS
20.88P/E
47.19BMarket Cap
Feb 03Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
525.89
624.29
692.01
701.29
770.82
854.51
927.29
1,039.19
1,144.46
1,294.61
1,480.88
1,657.89
- -
- -
Basic EPS, GAAP
1.21
-0.63
6.73
1.67
7.61
4.07
-16.65
7.48
8.15
8.62
7.6
8.02
- -
- -
Free Cash Flow per Basic Share
6.44
18.01
14.98
6.89
6.48
11.15
10.78
12.95
12.97
19.31
17.55
19.99
- -
- -
Dividend per Share
0.94
1.17
1.36
1.47
1.53
1.61
1.68
1.78
1.88
1.97
2.1
2.26
- -
1.87
Book Value per Share
8.82
2.98
9.68
9.47
13.76
13.92
-4.99
1.07
-1.03
2.6
3.31
7.78
- -
- -
Tangible Book Value per Share
-6.87
-26.69
-31.04
-31.25
-31.33
-29.61
-47.06
-67.59
-63.28
-67.15
-65.01
-82.21
- -
- -
Basic Weighted Avg Shares
227
218
212
218
218
210
205
206
208
203
199
194
193
193
Sales/Revenue/Turnover
119,569
135,962
146,850
153,144
167,940
179,589
189,894
213,989
238,587
262,173
293,959
321,333
- -
- -
Operating Margin (%)
1.01
1.01
1.24
1.32
1
1.12
1.07
1.33
1.15
1.02
1.07
1.22
- -
- -
Depreciation Expense
197
256
392
432
510
498
408
515
710
981
1,119
1,068
- -
- -
Net Income, GAAP
274
-138
1,428
364
1,658
855
-3,409
1,540
1,699
1,745
1,509
1,554
- -
- -
Effective Tax Rate (%)
57.94
151.37
- -
60.29
- -
11.68
- -
30.48
23.66
19.82
24.19
30.58
- -
- -
Profit Margin (%)
0.23
-0.1
0.97
0.24
0.99
0.48
-1.8
0.72
0.71
0.67
0.51
0.48
- -
- -
Working Capital
-450
-1,244
-2,429
-2,515
-1,975
-1,449
-797
-2,556
-3,888
-6,032
-6,559
-5,581
- -
- -
LT Debt
1,996
3,493
3,576
3,430
4,159
4,034
3,618
6,384
4,632
4,146
3,812
7,543
- -
- -
Total Equity
1,957
616
2,129
2,064
3,050
2,993
-840
584
71
666
787
1,747
- -
- -
Return on Invested Capital (%)
7.82
-5.17
- -
8.53
- -
16.01
- -
42.1
35.92
45.96
41.82
31.8
- -
- -
Return on Capital (%)
8.08
-4.82
- -
7.17
- -
13.71
- -
31.4
29.01
34.58
31.75
25.12
- -
- -
Return on Common Equity (%)
12.82
-10.74
104.01
17.38
66.37
29.44
- -
- -
- -
- -
258.42
144.31
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
203
279
- -
LT Borrowings
12,183
11,444
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
195
191
191
Market Capitalization
61,060
53,915
57,521

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
53,141
55,335
- -
Cash, Cash Equivalents & STI
2,176
2,815
- -
Accounts Receivable, Net
24,893
25,448
- -
Inventories
20,010
21,030
- -
Total Current Liabilities
56,132
59,197
- -
Payables & Accruals
55,078
58,048
- -
ST Debt
203
279
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
72,253
68,414
74,241
79,050
293,959
2025
81,487
75,454
80,664
83,729
321,333
2026
85,932
78,356
84,755
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.01
2.11
2.44
0.02
7.6
2025
2.52
3.7
3.55
-1.75
8.02
2026
2.88
8.44
3.95
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.53
0.54
0.52
0.51
2.1
2025
0.57
0.57
0.55
0.55
2.26
2026
0.65
0.6
0.6
- -
- -

Company Description

CEO
Robert P. Mauch
Full Time Employees
51,000
Sector
Distribution services
Industry
Medical distributors
Address
1 West First Avenue Conshohocken PA United States 19428-1800
IPO Date
May 28, 1996
Business
Cencora, Inc. (NYSE: COR) serves as a leading global pharmaceutical solutions organization that provides end-to-end pharmaceutical distribution, commercialization support, and related services to manufacturers, healthcare providers, pharmacies, hospitals, and health systems worldwide. Founded in 1871 and headquartered in Conshohocken, Pennsylvania, the company operates through U.S. Healthcare Solutions and International Healthcare Solutions segments; it distributes brand-name, specialty brand-name, generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment; offers wholesale and specialty distribution, pharmacy solutions, provider solutions, hospital and health system solutions, logistics and warehousing, drug research and clinical development support, commercialization support, and patient access and adherence programs; and serves acute care hospitals, independent and chain retail pharmacies, mail-order facilities, physicians, clinics, long-term care, assisted living centers, workers' compensation patients, and alternate site facilities across the United States, Canada, and other international markets. In recent developments, Cencora changed its name from AmerisourceBergen Corporation in August 2023; entered a definitive agreement in November 2024 to acquire Retina Consultants of America, a management services organization for retina specialists, for approximately $4.6 billion in cash plus up to $500 million in contingent consideration to expand its specialty capabilities and physician relationships; and announced in November 2025 a $1 billion investment through 2030 to strengthen its U.S. distribution network, including a new 530,000-square-foot national distribution center in Harrison, Ohio by spring 2027, expansions in Fontana, California and Dothan, Alabama with advanced automation and increased refrigerated capacity, and enhanced global cold chain logistics with a new third-party logistics facility planned in Italy in 2026.

Company News

  • Nike Among 13 Dividend Growth Companies To Announce Annual Dividend Increases In Latter Half Of November

  • US FTC sues to block Cencora's $3.5 billion sale of veterinary unit to Covetrus

  • Cencora, Inc. $COR Shares Bought by Ethic Inc.

  • ABC News veterans take buyouts as Disney continues to cut costs, and staffers worry about ‘brain drain'

  • Dividend Announcements: October 31-November 6, 2026 (Part 2 Of 2)

  • 3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility

  • What Cencora (COR) Said on Its Q4 Earnings Call

  • Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand

  • Cencora, Inc. (COR) Q4 2026 Earnings Call Transcript

  • Cencora (COR) Reports Q4 Earnings: What Key Metrics Have to Say

  • Cencora (COR) Surpasses Q4 Earnings and Revenue Estimates

  • Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results

  • Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and Focus

  • Why Cencora (COR) is a Top Growth Stock for the Long-Term

  • BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Lumentum Holdings Inc. (Nasdaq – LITE), Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC), American Oncology Network, Inc. (OTCQX – AONC)

  • Emerson Among 14 Dividend Growth Companies To Announce Annual Dividend Increases In First Half Of November

  • Cencora Gears Up to Report Q4 Results: How to Play the Stock?

  • Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key Metrics

  • Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth

  • Cencora to Acquire AON in $2.4B Deal to Expand Oncology Network